Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 known ✓ | P00915 | 2/20 | 0.46 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.46 |
| ▸ | PPARA | Q07869 | 4/20 | 0.67 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.57 |
| ▸ | FAAH | O00519 | 2/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4450091 | 1.00 | PPARA (0.67) | PPARAEPHX2FAAHTRPV1CA1 | |
| SCHEMBL27182799 | 0.89 | PPARA (0.59) | PPARAEPHX2CA1CA2 | |
| SCHEMBL2591113 | 0.89 | PPARA (0.59) | PPARAEPHX2CA1CA2 | |
| SCHEMBL124443 | 0.89 | PPARA (0.59) | PPARAEPHX2CA1CA2 | |
| SCHEMBL6836035 | 0.89 | PPARA (0.59) | PPARAEPHX2CA1CA2 | |
| SCHEMBL2591709 | 0.89 | PPARA (0.59) | PPARAEPHX2CA1CA2 | |
| SCHEMBL2588569 | 0.89 | PPARA (0.59) | PPARAEPHX2CA1CA2 | |
| Methane SCHEMBL1953352 | 0.87 | PPARA (0.57) | PPARAEPHX2CA1CA2 | |
| SCHEMBL127011 | 0.87 | PPARA (0.56) | PPARAEPHX2CA1CA2 | |
| SCHEMBL29026598 | 0.85 | PPARA (0.59) | PPARACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102434-A1 | USES OF PURINE NUCLEOSIDASE AND AMP PHOSPHORYLASE | CODEXIS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-12612605-B2 | Carboxyesterase polypeptides for kinetic resolution | CODEXIS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-12565641-B2 | Engineered terminal deoxynucleotidyl transferase variants | CODEXIS, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| EP-4687951-A1 | P450-BM3 VARIANTS WITH IMPROVED ACTIVITY | Codexis, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260022366-A1 | ENGINEERED NITROALDOLASES | CODEXIS INC (US) | 2026-01-22 | — | — | US | disclosed |
| WO-2025264722-A1 | ENGINEERED 3'O-KINASE VARIANTS | CODEXIS, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| WO-2025264715-A1 | ENGINEERED PYRUVATE OXIDASE VARIANTS | 0/CODEXIS, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20250388940-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | CODEXIS, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-12473557-B2 | Engineered guanylate kinase variant enzymes | CODEXIS, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250346870-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | CODEXIS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-5962292-A | L-PROLINE-3-HYDROXYLASE FOR EFFICIENT INDUSTRIAL HYDROXYLATION OF L-PROLINE IN PRESENCE OF 2-KETOGLUTARIC ACID AND DIVALENT IRON ION; END PRODUCT USED AS RAW MATERIAL FOR DRUGS OR ADDITIVES IN FOOD | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1999-10-05 | — | — | US | disclosed |
| EP-0542240-B1 | Process for producing flavine nucleotides | KYOWA HAKKO KOGYO KK (JP) | 1999-03-31 | — | — | EP | disclosed |
| US-5854040-A | Process for producing trans-4-hydroxy-L-proline | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1998-12-29 | — | — | US | disclosed |
| EP-0645457-B1 | L-proline-3-hydroxylase and process for producing cis-3-hydroxy-L-proline | KYOWA HAKKO KOGYO KK (JP) | 1998-04-01 | — | — | EP | disclosed |
| EP-0771876-A1 | PROCESS FOR PRODUCING cis-3-HYDROXY-L-PROLINE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1997-05-07 | — | — | EP | disclosed |
| EP-0759472-A1 | PROCESS FOR PRODUCING TRANS-4-HYDROXY-L-PROLINE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1997-02-26 | — | — | EP | disclosed |
| US-5514574-A | Method of producing flavine nucleotides | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1996-05-07 | — | — | US | disclosed |
| EP-0645457-A2 | Process for producing cis-3-hydroxy-L-proline | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1995-03-29 | — | — | EP | disclosed |
| EP-0641862-A2 | Process for producing trans-4-hydroxy-l-proline | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1995-03-08 | — | — | EP | disclosed |
| EP-0542240-A2 | Process for producing flavine nucleotides | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1993-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022366-A1 | ENGINEERED NITROALDOLASES | NOS2, NOS1, NOS3 | CA1 2245/4885CA2 2044/4885PPARA 2430/4885 |
| US-12565641-B2 | Engineered terminal deoxynucleotidyl transferase variants | DNTT, RNGTT, POLM | CA1 4319/4885CA2 3811/4885PPARA 3322/4885 |
| US-20250346870-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | AKR1C4, AKR7A2, AKR1C2 | CA1 4627/4885CA2 4818/4885PPARA 3414/4885 |
| US-12612605-B2 | Carboxyesterase polypeptides for kinetic resolution | CES1, CPA1, RNGTT | CA1 1552/4885CA2 767/4885PPARA 3731/4885 |
| US-20250388940-A1 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | DCXR, PDXK, XDH | CA1 4708/4885CA2 4732/4885PPARA 3221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.